The Potential Beneficial Role of Glucagon-like Peptide-1 in Endothelial Dysfunction and Heart Failure Associated with Insulin Resistance

Abstract

Endothelial dysfunction is a major characteristic of the atherosclerotic process and can be used to predict the outcome of cardiovascular disease in humans. Together with obesity and insulin resistance, such dysfunction is common among patients with type 2 diabetes and may explain their poor prognosis in connection with such a disease. Insulin resistance in skeletal muscle, adipose tissue, and the liver, a well-characterized feature of obesity and type 2 diabetes, contributes to the impairment of glucose homeostasis. Furthermore, the myocardial muscle can also be resistant to insulin, which might, at least in part, explain the frequent development of heart failure in individuals suffering from type 2 diabetes. The relationship between insulin resistance and endothelial dysfunction has prompted investigations, which reveal that regular exercise, dietary changes, and/or pharmacological agents can both increase insulin sensitivity and improve endothelial function. Glucagon-like peptide-1, an incretin, lowers blood levels of glucose and offers a promising new approach to the treatment of type 2 diabetes mellitus. Its extensive extra-pancreatic effects, including a favorable influence on cardiovascular parameters, are extremely interesting in this connection. The potential pharmacological effects of glucagon-like peptide-1 and its analogues on the endothelium and the heart are discussed in the present review.

Key words

cardiovascular disease - endothelial dysfunction - glucagon-like peptide-1 (GLP-1) - heart failure - insulin resistance

References

• 1 Zimmet PZ, Alberti KG. The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress.  Lancet. 1997;  350 ((Suppl 1)) SI1-SI4
• 2 Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.  N Engl J Med. 1998;  339 229-234
• 3 Ross R. Atherosclerosis – an inflammatory disease.  N Engl J Med. 1999;  340 115-126
• 4 Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes  Jr  DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.  Circulation. 2000;  101 948-954
• 5 Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease.  Circulation. 2000;  101 1899-1906
• 6 Neunteufl T, Heher S, Katzenschlager R, Wolfl G, Kostner K, Maurer G, Weidinger F. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain.  Am J Cardiol. 2000;  86 207-210
• 7 Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.  Diabetes Care. 2004;  27 813-823
• 8 Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective.  Endocr Rev. 2001;  22 36-52
• 9 Sjöholm A, Nyström T. Endothelial inflammation in insulin resistance.  Lancet. 2005;  365 610-612
• 10 Yudkin JS. Inflammation, obesity and the metabolic syndrome.  Horm Metab Res. 2007;  39 707-709
• 11 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.  N Engl J Med. 2003;  348 383-393
• 12 Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance.  Circulation. 2000;  101 1780-1784
• 13 Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.  J Clin Invest. 1996;  97 2601-2610
• 14 Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids.  Diabetologia. 2002;  45 623-634
• 15 Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes.  Diabetes. 1999;  48 1856-1862
• 16 Yki-Järvinen H. Insulin resistance and endothelial dysfunction.  Best Pract Res Clin Endocrinol Metab. 2003;  17 411-430
• 17 Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease.  Obes Res. 2003;  11 1278-1289
• 18 Szmitko PE, Wang CH, Weisel RD, Almeida JR de, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I.  Circulation. 2003;  108 1917-1923
• 19 Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II.  Circulation. 2003;  108 2041-2048
• 20 Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.  Nature. 1980;  288 373-376
• 21 Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase.  Am J Physiol Regul Integr Comp Physiol. 2003;  284 R1-R12
• 22 Yamamoto K, Sokabe T, Matsumoto T, Yoshimura K, Shibata M, Ohura N, Fukuda T, Sato T, Sekine K, Kato S, Isshiki M, Fujita T, Kobayashi M, Kawamura K, Masuda H, Kamiya A, Ando J. Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice.  Nat Med. 2006;  12 133-137
• 23 Gladwin MT, Schechter AN, Kim-Shapiro DB, Patel RP, Hogg N, Shiva S, Cannon  3rd  RO, Kelm M, Wink DA, Espey MG, Oldfield EH, Pluta RM, Freeman BA, Lancaster  Jr  JR, Feelisch M, Lundberg JO. The emerging biology of the nitrite anion.  Nat Chem Biol. 2005;  1 308-314
• 24 Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon  3rd  RO, Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation.  Nat Med. 2003;  9 1498-1505
• 25 Furchgott RF. The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide.  JAMA. 1996;  276 1186-1188
• 26 Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist.  Circulation. 2002;  105 546-549
• 27 Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries.  N Engl J Med. 1986;  315 1046-1051
• 28 Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction.  J Clin Invest. 1997;  100 2153-2157
• 29 Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose.  Am J Physiol. 1992;  263 H321-H326
• 30 Brownlee M. Biochemistry and molecular cell biology of diabetic complications.  Nature. 2001;  414 813-820
• 31 Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation.  Proc Natl Acad Sci USA. 2000;  97 12222-12226
• 32 Koya D, King GL. Protein kinase C activation and the development of diabetic complications.  Diabetes. 1998;  47 859-866
• 33 Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzuma K, Yamauchi T, Ha SW, Meier M, Rhodes CJ, King GL. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation.  Diabetes. 2000;  49 1239-1248
• 34 Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans.  Circ Res. 2002;  90 107-111
• 35 Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site.  J Clin Invest. 2001;  108 1341-1348
• 36 Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D, Sbraccia P, Spagnoli LG, Sesti G, Lauro R. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells.  Circulation. 2002;  106 466-472
• 37 Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects.  J Clin Invest. 2001;  108 635-636
• 38 Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo.  Circulation. 1998;  97 1695-1701
• 39 Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus.  J Clin Invest. 1996;  97 22-28
• 40 Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, Toda N, Kikkawa R. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta.  Diabetes. 1999;  48 2437-2445
• 41 Nyström T, Nygren A, Sjöholm A. Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease.  Am J Physiol Endocrinol Metab. 2004;  287 E919-E925
• 42 Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard  Jr  KA. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors.  Proc Natl Acad Sci USA. 1998;  95 9220-9225
• 43 Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2⁺/calmodulin-dependent and tetrahydrobiopterin regulatory process.  J Biol Chem. 1998;  273 25804-25808
• 44 Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus.  Diabetologia. 2000;  43 1435-1438
• 45 Ihlemann N, Rask-Madsen C, Perner A, Dominguez H, Hermann T, Køber L, Torp-Pedersen C. Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects.  Am J Physiol Heart Circ Physiol. 2003;  285 H875-H882
• 46 Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia.  J Clin Invest. 1997;  99 41-46
• 47 Ueda S, Matsuoka H, Miyazaki H, Usui M, Okuda S, Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers.  J Am Coll Cardiol. 2000;  35 71-75
• 48 Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D’Onofrio F. Vascular effects of acute hyperglycemia in humans are reversed by l-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia.  Circulation. 1997;  95 1783-1790
• 49 Fard A, Tuck CH, Donis JA, Sciacca R, Tullio MR Di, Wu HD, Bryant TA, Chen NT, Torres-Tamayo M, Ramasamy R, Berglund L, Ginsberg HN, Homma S, Cannon PJ. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes.  Arterioscler Thromb Vasc Biol. 2000;  20 2039-2044
• 50 Saltiel AR. Series introduction: the molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases.  J Clin Invest. 2000;  106 163-164
• 51 Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation.  J Clin Invest. 1997;  100 1230-1239
• 52 Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease.  Circulation. 1997;  96 3266-3268
• 53 Taddei S, Virdis A, Mattei P, Natali A, Ferrannini E, Salvetti A. Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension.  Circulation. 1995;  92 2911-2918
• 54 Nyström T, Nygren A, Sjöholm A. Persistent endothelial dysfunction is related to elevated C-reactive protein (CRP) levels in type II diabetic patients after acute myocardial infarction.  Clin Sci (Lond). 2005;  108 121-128
• 55 Nyström T, Nygren A, Sjöholm A. Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction.  Clin Sci (Lond). 2006;  110 673-681
• 56 Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Caselli A, Caballero AE, Economides PA, Veves A, Horton ES. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome.  Diabetes Care. 2003;  26 2119-2125
• 57 Rask-Madsen C, Dominguez H, Ihlemann N, Hermann T, Køber L, Torp-Pedersen C. Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans.  Circulation. 2003;  108 1815-1821
• 58 Yudkin JS, Panahloo A, Stehouwer C, Emeis JJ, Bulmer K, Mohamed-Ali V, Denver AE. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects.  Diabetologia. 2000;  43 1099-1106
• 59 Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones.  Trends Endocrinol Metab. 2003;  14 137-145
• 60 Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway.  Circulation. 2000;  102 1296-1301
• 61 Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men.  JAMA. 2004;  291 1730-1737
• 62 Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells.  FASEB J. 1999;  13 1231-1238
• 63 Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes.  Nature. 2001;  409 307-312
• 64 Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance.  Obes Res. 2002;  10 1-5
• 65 Sunden-Cullberg J, Nyström T, Lee ML, Mullins GE, Tokics L, Andersson J, Norrby-Teglund A, Treutiger CJ. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock.  Crit Care Med. 2007;  35 1536-1542
• 66 Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans.  Circulation. 2005;  111 932-939
• 67 Festa A, D’Agostino  Jr  R, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation.  Int J Obes Relat Metab Disord. 2001;  25 1407-1415
• 68 Festa A, Hanley AJ, Tracy RP, D’Agostino  Jr  R, Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion.  Circulation. 2003;  108 1822-1830
• 69 Esposito K, Pontillo A, Palo C Di, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.  JAMA. 2003;  289 1799-1804
• 70 Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes.  Diabetes Care. 2004;  27 2450-2457
• 71 Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, D’Andrea F, Molinari AM, Giugliano D. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year.  Circulation. 2002;  105 804-809
• 72 Shulman GI. Cellular mechanisms of insulin resistance.  J Clin Invest. 2000;  106 171-176
• 73 Graham TE, Kahn BB. Tissue-specific alterations of glucose transport and molecular mechanisms of intertissue communication in obesity and type 2 diabetes.  Horm Metab Res. 2007;  39 717-721
• 74 Kahn BB, Flier JS. Obesity and insulin resistance.  J Clin Invest. 2000;  106 473-481
• 75 Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism.  Nature. 2001;  414 799-806
• 76 Bar RS, Hoak JC, Peacock ML. Insulin receptors in human endothelial cells: identification and characterization.  J Clin Endocrinol Metab. 1978;  47 699-702
• 77 Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL, Kahn CR. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance.  J Clin Invest. 2003;  111 1373-1380
• 78 Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM.  Diabetes. 1992;  41 1076-1083
• 79 Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans.  J Clin Invest. 1994;  94 2511-2515
• 80 Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release.  J Clin Invest. 1994;  94 1172-1179
• 81 Yki-Järvinen H, Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology?.  Diabetologia. 1998;  41 369-379
• 82 Steinberg HO, Baron AD. Insulin-mediated vasodilation: why one's physiology could be the other's pharmacology.  Diabetologia. 1999;  42 493-495
• 83 Clark MG, Colquhoun EQ, Rattigan S, Dora KA, Eldershaw TP, Hall JL, Ye J. Vascular and endocrine control of muscle metabolism.  Am J Physiol. 1995;  268 E797-E812
• 84 Clark MG, Wallis MG, Barrett EJ, Vincent MA, Richards SM, Clerk LH, Rattigan S. Blood flow and muscle metabolism: a focus on insulin action.  Am J Physiol Endocrinol Metab. 2003;  284 E241-E258
• 85 Rattigan S, Clark MG, Barrett EJ. Hemodynamic actions of insulin in rat skeletal muscle: evidence for capillary recruitment.  Diabetes. 1997;  46 1381-1388
• 86 Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells.  J Clin Invest. 1996;  98 894-898
• 87 Zeng G, Nyström FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells.  Circulation. 2000;  101 1539-1545
• 88 Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+but requires phosphorylation by Akt at Ser(1179).  J Biol Chem. 2001;  276 30392-30398
• 89 Federici M, Pandolfi A, Filippis EA De, Pellegrini G, Menghini R, Lauro D, Cardellini M, Romano M, Sesti G, Lauro R, Consoli A. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells.  Circulation. 2004;  109 399-405
• 90 Jansson PA, Pellme F, Hammarstedt A, Sandqvist M, Brekke H, Caidahl K, Forsberg M, Volkmann R, Carvalho E, Funahashi T, Matsuzawa Y, Wiklund O, Yang X, Taskinen MR, Smith U. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin.  FASEB J. 2003;  17 1434-1440
• 91 Gaenzer H, Neumayr G, Marschang P, Sturm W, Lechleitner M, Foger B, Kirchmair R, Patsch J. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus.  Am J Cardiol. 2002;  89 431-434
• 92 Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Järvinen H. Insulin therapy improves endothelial function in type 2 diabetes.  Arterioscler Thromb Vasc Biol. 2000;  20 545-550
• 93 Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Køber L, Nervil Kistorp C, Torp-Pedersen C. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease.  Diabetes. 2001;  50 2611-2618
• 94 Campia U, Sullivan G, Bryant MB, Waclawiw MA, Quon MJ, Panza JA. Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile.  Am J Physiol Heart Circ Physiol. 2004;  286 H76-H82
• 95 Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, Bonadonna RC. Insulin causes endothelial dysfunction in humans: sites and mechanisms.  Circulation. 2002;  105 576-582
• 96 Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells.  J Biol Chem. 2002;  277 1794-1799
• 97 Hsueh WA, Law RE. Insulin signaling in the arterial wall.  Am J Cardiol. 1999;  84 21J-24J
• 98 Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats.  J Clin Invest. 1999;  104 447-457
• 99 Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.  J Clin Invest. 2000;  105 311-320
• 100 Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes.  Nat Clin Pract Endocrinol Metab. 2007;  3 46-56
• 101 Zethelius B, Byberg L, Hales CN, Lithell H, Berne C. Proinsulin is an independent predictor of coronary heart disease: Report from a 27-year follow-up study.  Circulation. 2002;  105 2153-2158
• 102 Kieffer TJ, Habener JF. The glucagon-like peptides.  Endocr Rev. 1999;  20 876-913
• 103 Gutniak M, Ørskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus.  N Engl J Med. 1992;  326 1316-1322
• 104 Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.  JAMA. 2007;  298 194-206
• 105 Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.  Lancet. 2006;  368 1696-1705
• 106 D’Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.  Am J Physiol Endocrinol Metab. 2004;  286 E882-E890
• 107 Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.  Lancet. 2002;  359 824-830
• 108 Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.  J Clin Endocrinol Metab. 2002;  87 3768-3773
• 109 Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.  J Clin Endocrinol Metab. 2001;  86 3717-3723
• 110 Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.  Diabetologia. 2002;  45 1410-1415
• 111 Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.  Diabetes. 2000;  49 611-617
• 112 Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.  Proc Natl Acad Sci USA. 1992;  89 8641-8645
• 113 Dillon JS, Tanizawa Y, Wheeler MB, Leng XH, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA, Boyd  3rd  AE. Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor.  Endocrinology. 1993;  133 1907-1910
• 114 Graziano MP, Hey PJ, Borkowski D, Chicchi GG, Strader CD. Cloning and functional expression of a human glucagon-like peptide-1 receptor.  Biochem Biophys Res Commun. 1993;  196 141-146
• 115 Stoffel M, Espinosa  3rd  R, Le Beau MM, Bell GI. Human glucagon-like peptide-1 receptor gene Localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6.  Diabetes. 1993;  42 1215-1218
• 116 Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.  Diabetes. 1993;  42 1678-1682
• 117 Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.  J Biol Chem. 1993;  268 19650-19655
• 118 Fehmann HC, Jiang J, Schweinfurth J, Dorsch K, Wheeler MB, Boyd  3rd  AE, Göke B. Ligand-specificity of the rat GLP-I receptor recombinantly expressed in Chinese hamster ovary (CHO-) cells.  Z Gastroenterol. 1994;  32 203-207
• 119 Holz GGt, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).  Nature. 1993;  361 362-365
• 120 Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.  Pflugers Arch. 1998;  435 583-594
• 121 Lu M, Wheeler MB, Leng XH, Boyd  3rd  AE. The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I (7–37).  Endocrinology. 1993;  132 94-100
• 122 Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.  Diabetes. 1999;  48 2270-2276
• 123 Edvell A, Lindström P. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea+/?.  Endocrinology. 1999;  140 778-783
• 124 Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, Egan JM. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.  Diabetes. 2000;  49 741-748
• 125 Barragán JM, Rodriguez RE, Blázquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7–36) amide in rats.  Am J Physiol. 1994;  266 E459-E466
• 126 Barragán JM, Rodriguez RE, Eng J, Blázquez E. Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.  Regul Pept. 1996;  67 63-68
• 127 Ørskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I.  Diabetes. 1996;  45 832-835
• 128 Barragán JM, Eng J, Rodriguez R, Blázquez E. Neural contribution to the effect of glucagon-like peptide-1-(7–36) amide on arterial blood pressure in rats.  Am J Physiol. 1999;  277 E784-E791
• 129 Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.  J Clin Invest. 2002;  110 43-52
• 130 Bojanowska E, Stempniak B. Effects of centrally or systemically injected glucagon-like peptide-1 (7–36) amide on release of neurohypophysial hormones and blood pressure in the rat.  Regul Pept. 2000;  91 75-81
• 131 Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, Elmquist JK. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites.  J Neurosci. 2003;  23 2939-2946
• 132 Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7–36) amide and amylin on the pulmonary circulation of the rat.  Regul Pept. 2001;  102 81-86
• 133 Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism.  Regul Pept. 2005;  125 173-177
• 134 Richter G, Feddersen O, Wagner U, Barth P, Göke R, Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery.  Am J Physiol. 1993;  265 L374-L381
• 135 Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC, D’Alessio D. The role of CNS glucagon-like peptide-1 (7–36) amide receptors in mediating the visceral illness effects of lithium chloride.  J Neurosci. 2000;  20 1616-1621
• 136 Davis  Jr  HR, Mullins DE, Pines JM, Hoos LM, France CF, Compton DS, Graziano MP, Sybertz EJ, Strader CD, Heek M Van. Effect of chronic central administration of glucagon-like peptide-1(7–36) amide on food consumption and body weight in normal and obese rats.  Obes Res. 1998;  6 147-156
• 137 Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding.  Nature. 1996;  379 69-72
• 138 Gardiner SM, March JE, Kemp PA, Bennett T. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats.  J Pharmacol Exp Ther. 2006;  316 852-885
• 139 Bojanowska E, Stempniak B. Effects of glucagon-like peptide-1 (7–36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat.  J Endocrinol. 2002;  172 303-310
• 140 Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat.  Endocrinology. 1997;  138 4445-4455
• 141 Zueco JA, Esquifino AI, Chowen JA, Alvarez E, Castrillon PO, Blazquez E. Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1(7–36) amide on vasopressin and oxytocin release.  J Neurochem. 1999;  72 10-16
• 142 Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.  Diabetes Obes Metab. 2006;  8 436-447
• 143 Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.  Diabetes Care. 2007;  30 1608-1610
• 144 Rask E, Olsson T, Söderberg S, Johnson O, Seckl J, Holst JJ, Ahren B. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.  Diabetes Care. 2001;  24 1640-1645
• 145 Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.  Diabetes Care. 1999;  22 1137-1143
• 146 Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.  Am J Physiol Heart Circ Physiol. 2005;  289 H2401-H2408
• 147 Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet.  Diabetes Care. 1996;  19 843-848
• 148 Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.  Am J Physiol Endocrinol Metab. 2004;  287 E1209-E1215
• 149 Edwards CM, Todd JF, Ghatei MA, Bloom SR. Subcutaneous glucagon-like peptide-1 (7–36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects.  Clin Sci (Lond). 1998;  95 719-724
• 150 Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of glucagon-like peptide-1 (GLP-1) on endothelial function in humans. Dampening by glyburide but not by glimepiride.  Am J Physiol Endocrinol Metab. 2007;  293 E1289-E1295
• 151 Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats.  J Hypertens. 2003;  21 1125-1135
• 152 Özyazgan S, Kutluata N, Af S, Ozda SB, Akkan AG. Effect of glucagon-like peptide-1(7–36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.  Pharmacology. 2005;  74 119-126
• 153 Tütüncü Ö, Nathanson D, Zangh F, Sjöholm Å, Nyström T, Zangh Q. Exendin-4 rapidly increases nitric oxide production, promotes proliferation and protects against glucolipoapoptosis in human coronary artery endothelial cells.  Diabetologia. 2007;  50 S16
• 154 Liu H, Hu Y, Simpson RW, Dear AE. Glucagon-like peptide-1 attenuates TNFalpha-mediated induction of PAI-1 expression.  J Endocrinology. 2008;  196 57-65
• 155 Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor.  Nature. 1990;  348 730-732
• 156 Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor.  Nature. 1990;  348 732-735
• 157 Nucci G de, Thomas R, D’Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.  Proc Natl Acad Sci USA. 1988;  85 9797-9800
• 158 Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang Q, Drucker DJ, Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor.  Endocrinology. 2003;  144 2242-2252
• 159 Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, Isea JE, Romero G. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group.  Circulation. 1998;  98 2227-2234
• 160 Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group.  BMJ. 1997;  314 1512-1515
• 161 Horst IC van der, Zijlstra F, van’t Hof AW, Doggen CJ, Boer MJ de, Suryapranata H, Hoorntje JC, Dambrink JH, Gans RO, Bilo HJ. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial.  J Am Coll Cardiol. 2003;  42 784-791
• 162 Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes.  Crit Care Med. 2004;  32 848-851
• 163 Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, Elahi D, Shannon RP. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines.  J Pharmacol Exp Ther. 2005;  312 303-308
• 164 Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.  Circulation. 2004;  110 955-961
• 165 Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.  Circulation. 2004;  109 962-965
• 166 Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts.  J Pharmacol Exp Ther. 2006;  317 1106-1113
• 167 Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern  Jr  GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting.  Am J Cardiol. 2007;  100 824-829
• 168 Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.  Diabetes. 2005;  54 146-151
• 169 Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G, Gutniak M. Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium.  Peptides. 2003;  24 569-578
• 170 Vila Petroff MG, Egan JM, Wang X, Sollott SJ. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes.  Circ Res. 2001;  89 445-452
• 171 MacFalls EO, Hou M, Bache RJ, Best A, Marx D, Sikora J, Ward HB. Activation of p38 MAPK and increased glucose transport in chronic hibernating swine myocardium.  Am J Physiol Heart Circ Physiol. 2004;  287 H1328-H1334
• 172 Maiorana A, O’Driscoll G, Cheetham C, Dembo L, Stanton K, Goodman C, Taylor R, Green D. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes.  J Am Coll Cardiol. 2001;  38 860-866
• 173 Esposito K, Marfella R, Ciotola M, Palo C Di, Giugliano F, Giugliano G, D’Armiento M, D’Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial.  JAMA. 2004;  292 1440-1446
• 174 Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.  Diabetes Care. 1997;  20 537-544
• 175 Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
• 176 Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
• 177 Ban K, Noyan-Ashraf MH, Hoefer J. et al . Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.  Circulation. 2008;  117 2340-2350
• 178 Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia-reperfusion injury in rat heart.  Regul Pept. 2008;  146 243-249

Correspondence